https://idwiki.org/index.php?action=history&feed=atom&title=Drug-induced_vasculitis 2026-04-29T23:51:53Z Revision history for this page on the wiki MediaWiki 1.43.8 https://idwiki.org/index.php?title=Drug-induced_vasculitis&diff=5128&oldid=prev 2020-07-21T01:52:45Z

<p>Text replacement - &quot;Clinical Presentation&quot; to &quot;Clinical Manifestations&quot;</p> <table style="background-color: #fff; color: #202122;" data-mw="interface"> <col class="diff-marker" /> <col class="diff-content" /> <col class="diff-marker" /> <col class="diff-content" /> <tr class="diff-title" lang="en"> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">← Older revision</td> <td colspan="2" style="background-color: #fff; color: #202122; text-align: center;">Revision as of 01:52, 21 July 2020</td> </tr><tr> <td colspan="2" class="diff-lineno">Line 11:</td> <td colspan="2" class="diff-lineno">Line 11:</td> </tr> <tr> <td class="diff-marker"></td> <td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* Long list: [[ofloxacin]], [[ciprofloxacin]], [[lomefloxacin]], [[tetracycline]], [[imipenem/cilastatin]], [[cefaclor]], [[cefuroxime]], [[vancomycin]], [[teicoplanin]], [[clarithromycin]], [[azithromycin]]/[[roxithromycin]], [[rifampin]], [[TMP/SMX]], [[nitrofurantoin]], [[mefloquine]], [[piperazine]]</div></td> <td class="diff-marker"></td> <td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* Long list: [[ofloxacin]], [[ciprofloxacin]], [[lomefloxacin]], [[tetracycline]], [[imipenem/cilastatin]], [[cefaclor]], [[cefuroxime]], [[vancomycin]], [[teicoplanin]], [[clarithromycin]], [[azithromycin]]/[[roxithromycin]], [[rifampin]], [[TMP/SMX]], [[nitrofurantoin]], [[mefloquine]], [[piperazine]]</div></td> </tr> <tr> <td class="diff-marker"></td> <td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br /></td> <td class="diff-marker"></td> <td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><br /></td> </tr> <tr> <td class="diff-marker" data-marker="−"></td> <td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;"><div>== Clinical <del style="font-weight: bold; text-decoration: none;">Presentation</del> ==</div></td> <td class="diff-marker" data-marker="+"></td> <td style="color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;"><div>== Clinical <ins style="font-weight: bold; text-decoration: none;">Manifestations</ins> ==</div></td> </tr> <tr> <td class="diff-marker"></td> <td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* Most commonly starts after 4 to 7 days of exposure</div></td> <td class="diff-marker"></td> <td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* Most commonly starts after 4 to 7 days of exposure</div></td> </tr> <tr> <td class="diff-marker"></td> <td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* Most common presenting complaint is palpable purpura (84%), mainly in the lower extremities</div></td> <td class="diff-marker"></td> <td style="background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;"><div>* Most common presenting complaint is palpable purpura (84%), mainly in the lower extremities</div></td> </tr> <!-- diff cache key site7_mediawiki:diff:1.41:old-3376:rev-5128:wikidiff2=table:1.13.0:bc2a06be --> </table>

Aidan https://idwiki.org/index.php?title=Drug-induced_vasculitis&diff=3376&oldid=prev 2020-01-15T15:36:57Z

<p>Initial creations</p> <p><b>New page</b></p><div>== Background ==<br /> === Pathophysiology ===<br /> * Unclear, but likely involves immune complex deposition<br /> <br /> === Etiology ===<br /> * [[Minocycline]]: p-ANCA vasculitis similar to PAN<br /> * [[Rifampin]]: cutaneous vasculitis<br /> * [[Penicillins]]: cutaneous or visceral vasculitis similar to PAN<br /> * [[Sulfonamides]]: vasculitis similar to PAN<br /> * [[Fluoroquinolones]]: vasculitis<br /> * Long list: [[ofloxacin]], [[ciprofloxacin]], [[lomefloxacin]], [[tetracycline]], [[imipenem/cilastatin]], [[cefaclor]], [[cefuroxime]], [[vancomycin]], [[teicoplanin]], [[clarithromycin]], [[azithromycin]]/[[roxithromycin]], [[rifampin]], [[TMP/SMX]], [[nitrofurantoin]], [[mefloquine]], [[piperazine]]<br /> <br /> == Clinical Presentation ==<br /> * Most commonly starts after 4 to 7 days of exposure<br /> * Most common presenting complaint is palpable purpura (84%), mainly in the lower extremities<br /> ** Other dermatologic manifestations include maculopapular rash (25%) and urticaria or nodules (1% each)<br /> * Also common is acute arthritis (65%), mainly an oligoarthritis in the legs (ankles and knees)<br /> * May have fever (23%)<br /> * May have nephropathy (7%), but usually mild<br /> * May have positive ANCA antibodies<br /> <br /> == Management ==<br /> * Generally self-limited following withdrawal of offending medication<br /> * NSAIDs if symptomatic arthritis<br /> * Occasionally prednisone<br /> * Although unclear, should probably not be challenged with other medication in the same class<br /> <br /> == Further Reading ==<br /> * Martinez-Taboada VM, &#039;&#039;et al&#039;&#039;. Clinical Features and Outcome of 95 Patients With Hypersensitivity Vasculitis. &#039;&#039;Am J Med&#039;&#039;. 1997;107(2):186-191. DOI: [https://doi.org/10.1016/S0002-9343(96)00405-6 10.1016/S0002-9343(96)00405-6]<br /> * ten Holder SM, Joy MS, Falk RJ. Cutaneous and Systemic Manifestations of Drug-Induced Vasculitis. &#039;&#039;Ann Pharmacother&#039;&#039;. 2002;36:130-147. DOI: [https://doi.org/10.1345/aph.1A124 10.1345/aph.1A124]<br /> <br /> [[Category:Adverse effects of antibiotics]]</div>

Aidan